AWARDS

Young Investigator Awards

One of the most important initiatives of ACTRIMS and ECTRIMS is to foster the careers of young scientists. It is a pleasure to hear and learn from Young Investigators and award their work. Please join us in congratulating our MSVirtual2020 Young Investigator Awardees!

BEST YOUNG INVESTIGATOR ORAL PRESENTATIONS
Adil Harroud, University of California, San Francisco
FC04.05.05 - Understanding the relative contributions of obesity, vitamin D, leptin, and adiponectin to MS risk: a Mendelian randomization mediation analysis

Mary Horton, University of California, Berkeley
LB01.05 - Network analysis identifies gut bacteria associated with multiple sclerosis relapse among pediatric-onset patients

BEST YOUNG INVESTIGATOR POSTER PRESENTATIONS
Majid Pahlevan Kakhki, Karolinska Institute
P0526 - Methylome and transcriptome analysis implicates NBPF locus in PPMS etiopathology

Eliane Piket, Karolinska Institute
P0980 - MicroRNA-150 controls experimental autoimmune encephalomyelitis by regulating CD4 T cell differentiation and function 

Izanne Roos, Royal Melbourne Hospital
P0876 - High and low efficacy therapy in secondary progressive multiple sclerosis after accounting for therapeutic lag 

Myrte Strik, Amsterdam UMC
P0640 - Sensorimotor network dynamics predicts loss of upper and lower limb function in people with multiple sclerosis 

Thomas Williams, University College London
P0824 - Serum neurofilaments and cognition in secondary progressive multiple sclerosis

MSIF 2020 YOUNG INVESTIGATOR AWARD
The MS International Federation (MSIF) has awarded their 2020 Young Investigator Award to Helen Onuorah for her work on racial inequalities in MS research participation.

Helen’s research looks at the involvement of ethnic minority groups in Phase III MS trials. It also investigates the reporting of ethnicities in trials and post-marketing studies. People affected by MS from ethnic minority groups are underrepresented in MS trials and underreported in post-marketing studies assessing the safety and efficacy of DMTs. Research into these inequalities can help patients and healthcare professionals make informed decisions about MS care.